Astemizole
Clinical data | |
---|---|
AHFS/Drugs.com | Multum Consumer Information |
MedlinePlus | a600034 |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Fecal | |
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Astemizole (marketed under the brand name Hismanal, developmental code R43512) was a second-generation
Pharmacology
Astemizole is a histamine
Astemizole is rapidly absorbed from the gastrointestinal tract and competitively binds to histamine H1 receptor sites in the gastrointestinal tract, uterus, blood vessels, and bronchial muscle. This suppresses the formation of
Despite some earlier reports that astemizole does not cross the blood–brain barrier, several studies[4][5] have shown high permeability and high binding to protein folds associated with Alzheimer's.
Astemizole may also act on histamine H3 receptors, thereby producing adverse effects.[citation needed]
Astemizole does also act as FIASMA (functional inhibitor of acid sphingomyelinase).[6]
Astemizole has been researched as a treatment for Creutzfeldt-Jakob Disease (CJD).[7]
Toxicity
Astemizole has an oral